The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH AL 2020 | Allogeneic HSCT in patients with high-risk myeloma
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 trial, which compared tandem autologous transplant (auto-auto) versus autologous followed by reduced-intensity allogeneic (auto-allo) transplant in patients with newly diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
